Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes

Host: Naomi Fisher, MD
Guest: Florian Rader, MD

Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Andrew Keaveny, MD
Guest: Don Rockey, MD

Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.

Host: Mikhail Kosiborod, MD
Guest: Biff F. Palmer, MD

Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.

Host: Ashley Baker, MSN, PMHNP
Guest: Chi D. Chu, MD, MAS

The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep dive with Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.

Guest: Jessica E. Hawley M.D. M.S.

The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.

Host: Javed Butler, MD, MBA, MPH
Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S.

For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.

Guest: Jai Radhakrishnan, MD

The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.^1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York.

References:

1. Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501
2. Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000
3. Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092

319698 12/23

Guest: Richard Lafayette, MD, FACP

Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.¹ That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California.

References:

1. Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004

319698 12/23

Guest: Mark Haas, MD

Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),^1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles.

References:

1. Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02
2. Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254

319698 12/23

Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA

Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?